Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Enrollment will begin soon in 2018 for our Phase 3 PolarisDMD trial with edasalonexent in Duchenne muscular dystrophy.
September 19, 2018: Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress
August 9, 2018: Catabasis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Reviews Business Progress
August 8, 2018: Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team